PMID- 37208639
OWN - NLM
STAT- MEDLINE
DCOM- 20230522
LR  - 20230522
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 23
IP  - 1
DP  - 2023 May 19
TI  - Efficacy and safety of combined immunotherapy and antiangiogenic therapy for 
      advanced non-small cell lung cancer: a real-world observation study.
PG  - 175
LID - 10.1186/s12890-023-02470-z [doi]
LID - 175
AB  - PURPOSE: This study was performed to investigate the efficacy and safety of 
      combined immunotherapy and antiangiogenic therapy for advanced non-small cell 
      lung cancer (NSCLC) in the real world. METHODS: Data on clinicopathological 
      features, efficacy and adverse events (AEs) were collected retrospectively in 
      advanced NSCLC patients who received immunotherapy combined with antiangiogenic 
      therapy. RESULTS: A total of 85 advanced NSCLC patients were enrolled. The 
      patients had a median progression-free survival (PFS) of 7.9 months and a median 
      overall survival (OS) of 18.60 months. The objective response rate and disease 
      control rate were 32.9% and 83.5%, respectively. Subgroup analysis revealed that 
      NSCLC patients with stage IV (p = 0.042), brain metastasis (p = 0.016) and bone 
      metastasis (p = 0.016) had shorter PFS. NSCLC patients with brain metastasis 
      (p = 0.025), liver metastasis (p = 0.012), bone metastasis (p = 0.014) and EGFR 
      mutations (p = 0.033) had shorter OS. Multivariate analysis revealed that brain 
      metastasis (HR = 1.798, 95% CI: 1.038, 3.112, p = 0.036) and bone metastasis 
      (HR = 1.824, 95% CI: 1.077, 3.090, p = 0.025) were independent predictive factors 
      of PFS, and bone metastasis (HR = 2.00, 95% CI: 1.124, 3.558, p = 0.018) was an 
      independent predictive factor of OS. In addition, patients receiving 
      immunotherapy combined with antiangiogenic therapy in second-line therapy had 
      longer OS than those receiving immunotherapy in third- or later-line therapy 
      (p = 0.039). Patients with EGFR mutations who received combination therapy had 
      worse OS than those with KRAS mutations (p = 0.026). Furthermore, PD-L1 
      expression was associated with treatment responses in advanced NSCLC 
      (chi2 = 22.123, p = 0.000). AEs of different grades occurred in 92.9% (79/85) of 
      NSCLC patients, most of which were mild grade 1/2 AEs. No grade 5 fatal AEs 
      occurred. CONCLUSION: Immunotherapy combined with antiangiogenic therapy was an 
      option for advanced NSCLC patients with good safety and tolerability. Brain 
      metastases and bone metastases were potentially independent negative predictors 
      of PFS. Bone metastases were a potential independent negative predictor of OS. 
      PD-L1 expression was a potential predictor of response for immunotherapy combined 
      with antiangiogenic therapy.
CI  - (c) 2023. The Author(s).
FAU - Ma, Ke
AU  - Ma K
AD  - Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou 
      University, No.50 Building East Road, Zhengzhou, Henan, 450052, People's Republic 
      of China.
FAU - Guo, Qianqian
AU  - Guo Q
AD  - Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou 
      University, No.50 Building East Road, Zhengzhou, Henan, 450052, People's Republic 
      of China.
FAU - Li, Xingya
AU  - Li X
AD  - Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou 
      University, No.50 Building East Road, Zhengzhou, Henan, 450052, People's Republic 
      of China. fcclixy1@zzu.edu.cn.
LA  - eng
GR  - 212300410251/Natural Science Foundation of Henan Province/
GR  - 2018020022/Henan Medical Science and Technology Foundation/
PT  - Journal Article
DEP - 20230519
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
RN  - 0 (B7-H1 Antigen)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - *Lung Neoplasms/genetics
MH  - B7-H1 Antigen/metabolism
MH  - Retrospective Studies
MH  - Immunotherapy
MH  - ErbB Receptors/genetics
MH  - *Brain Neoplasms/therapy
PMC - PMC10197234
OTO - NOTNLM
OT  - Antiangiogenic therapy
OT  - Chemotherapy-free
OT  - Immunotherapy
OT  - Non-small cell lung cancer
COIS- The authors declare no competing interests.
EDAT- 2023/05/20 09:42
MHDA- 2023/05/22 06:43
PMCR- 2023/05/19
CRDT- 2023/05/19 23:34
PHST- 2022/11/02 00:00 [received]
PHST- 2023/05/04 00:00 [accepted]
PHST- 2023/05/22 06:43 [medline]
PHST- 2023/05/20 09:42 [pubmed]
PHST- 2023/05/19 23:34 [entrez]
PHST- 2023/05/19 00:00 [pmc-release]
AID - 10.1186/s12890-023-02470-z [pii]
AID - 2470 [pii]
AID - 10.1186/s12890-023-02470-z [doi]
PST - epublish
SO  - BMC Pulm Med. 2023 May 19;23(1):175. doi: 10.1186/s12890-023-02470-z.